Cedars-Sinai Cancer Scientists to Attend AACR Annual Meeting

Cedars-Sinai Cancer physicians and scientists will share the latest advances in cancer science and medicine at the American Association for Cancer Research (AACR) Annual Meeting April 17-22 in San Diego.

Through more than 20 talks, panels, symposia and poster presentations, they will cover topics ranging from cancer biology to the tumor microenvironment, biomarkers that can guide cancer treatment, clinical trial results, and the role of AI in precision oncology.

Late-Breaking Presentation

Inderjit Mehmi, MD, medical oncologist at Cedars-Sinai The Angeles Clinic and Research Institute, will deliver a late-breaking oral presentation about an ongoing Phase I/IIa study of the immune checkpoint inhibitor GV20-0251 in patients with advanced melanoma that is resistant to anti-PD1 and other standard therapies. The presentation builds on clinical data presented at ASCO 2025 and will report translational findings from the study.

Additional Cedars-Sinai Cancer Experts and Topics

Eytan Ruppin, MD, PhD, an investigator at the Translational Research Institute and the Jim and Eleanor Randall Department of Surgery,will chair an Advances in Technology session exploring approaches for harnessing AI to learn about the spatial organization of human tissues. Speakers will describe computational approaches to spatial omics experiments, recent studies on developing agents that facilitate the analysis and characterization of pathology slides and spatial transcriptomics data, and ways to infer spatial biology and cancer treatment response biomarkers directly from histopathology slides.

Sergei Grivennikov, PhD, professor of Medicine and Biomedical Sciences, will co-chair a mini-symposium on the tumor microenvironment and its role in tumor evolution and immune system evasion.

Karen Reckamp, MD, a thoracic medical oncologist and director of the Division of Medical Oncology, will present final results from Pragmatica-Lung, a prospective randomized clinical trial with a pragmatic design that evaluated ramucirumab plus pembrolizumab versus standard of care in more than 800 patients with stage 4 or recurrent non-small cell lung cancer.

Cedars-Sinai investigators will also present research on:

• New understanding of and treatments for breast cancer
• Disparities in heart disease deaths among breast cancer patients
• Antitumor responses in pancreatic and breast cancer
• Radiation and antitumor therapies in prostate cancer
• Immune rejection and antitumor activity in bile duct cancer
• The tumor microenvironment's role in pancreatic cancer spread

Experts Available to Comment

Cedars-Sinai investigators are available to discuss their work and other news coming out of the meeting. To schedule an interview, contact Christina Elston at [email protected] or 626-298-0702.